New Huntington's drug shows promise in early safety trial

NCT ID NCT06024265

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early phase 1 trial tested an experimental drug called ER2001 in 10 adults with early Huntington's disease. The drug was given by IV at increasing doses over 14 weeks to check safety and how the body processes it. The study also looked for early signs that the drug might affect the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ER2001 (an experimental drug given by intravenous injection)

What this could lead to

If successful, this could point toward a treatment that slows or controls Huntington's disease progression.

What could go wrong

This is a very early, small (10 people) phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510080, China